Pathobiology and diagnosis of follicular lymphoma

Seminars in Diagnostic Pathology

Volumn 28, Issue 2, 2011, Pages 146-160

  Klapper, Wolfram ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Grading; In situ follicular lymphoma; Pediatric follicular lymphoma; T(14; 18)

Indexed keywords

ARTICLE; BONE MARROW INFILTRATION; CANCER CLASSIFICATION; CANCER GRADING; CANCER INFILTRATION; CANCER MORPHOLOGY; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FOLLICULAR LYMPHOMA; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT;

HUMANS; LYMPHOMA, FOLLICULAR;

EID: 79957983943     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2011.02.006     Document Type: Article

References (56)

1. Swerdlow S.H., Campo E., Harris N. WHO Classification of Tumors of the Haematopoietic and Lymphoid Tissues 2008, IARC, Lyon.
2. Dave S.S., Wright G., Tan B., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159-2169.
3. Dogan A., Du M.Q., Aiello A., et al. Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood 1998, 91:4708-4714.
4. Kuppers R., Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 2001, 20:5580-5594.
5. Schuler F., Dolken L., Hirt C., et al. Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int J Cancer 2009, 124:958-963.
6. Roulland S., Lebailly P., Lecluse Y., et al. Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals. Leukemia 2006, 20:158-162.
7. Roulland S., Navarro J.M., Grenot P., et al. Follicular lymphoma-like B cells in healthy individuals: A novel intermediate step in early lymphomagenesis. J Exp Med 2006, 203:2425-2431.
8. Viardot A., Barth T.F., Moller P., et al. Cytogenetic evolution of follicular lymphoma. Semin Cancer Biol 2003, 13:183-190.
9. Viardot A., Moller P., Hogel J., et al. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol 2002, 20:4523-4530.
10. Scholtysik R., Kreuz M., Klapper W., et al. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica 2010, 95:2047-2055.
11. Davies A.J., Rosenwald A., Wright G., et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007, 136:286-293.
12. McDonnell T.J., Korsmeyer S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991, 349:254-256.
13. Morse H.C., Anver M.R., Fredrickson T.N., et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 2002, 100:246-258.
14. Klapper W., Hoster E., Rolver L., et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: The German Low Grade Lymphoma Study Group. J Clin Oncol 2007, 25:3330-3336.
15. Hans C.P., Weisenburger D.D., Vose J.M., et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003, 101:2363-2367.
16. Ganti A.K., Weisenburger D.D., Smith L.M., et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska Lymphoma Study Group Experience. Ann Oncol 2006, 17:920-927.
17. Schmid U., Cogliatti S.B., Diss T.C., et al. Monocytoid/marginal zone B-cell differentiation in follicle centre cell lymphoma. Histopathology 1996, 29:201-208.
18. Goodlad J.R., Batstone P.J., Hamilton D., et al. Follicular lymphoma with marginal zone differentiation: Cytogenetic findings in support of a high-risk variant of follicular lymphoma. Histopathology 2003, 42:292-298.
19. Hiraga J., Tomita A., Sugimoto T., et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: Its prevalence and clinical significance. Blood 2009, 113:4885-4893.
20. Katzenberger T., Kalla J., Leich E., et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 2009, 113:1053-1061.
21. Leich E., Salaverria I., Bea S., et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 2009, 114:826-834.
22. Bosga-Bouwer A.G., van Imhoff G.W., Boonstra R., et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003, 101:1149-1154.
23. Gaulard P., d'Agay M.F., Peuchmaur M., et al. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 1992, 140:1089-1095.
24. Masir N., Campbell L.J., Goff L.K., et al. BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol 2009, 144:716-725.
25. Ott G., Katzenberger T., Lohr A., et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002, 99:3806-3812.
26. Sukumar S., Conrad D.H., Szakal A.K., et al. Differential T cell-mediated regulation of CD23 (Fc epsilonRII) in B cells and follicular dendritic cells. J Immunol 2006, 176:4811-4817.
27. Naresh K.N. MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica 2007, 92:267-268.
28. Karube K., Guo Y., Suzumiya J., et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 2007, 109:3076-3079.
29. Klapper W., Wacker H.H. Follicular and mantle cell lymphoma: Extranodal involvement of primarily nodal indolent B-cell lymphomas [in German]. Pathologe 2006, 28:21-28.
30. Yamamoto S., Nakase H., Yamashita K., et al. Gastrointestinal follicular lymphoma: Review of the literature. J Gastroenterol 2010, 45:370-388.
31. Pileri S.A., Sabattini E., Rosito P., et al. Primary follicular lymphoma of the testis in childhood: An entity with peculiar clinical and molecular characteristics. J Clin Pathol 2002, 55:684-688.
32. Bacon C.M., Ye H., Diss T.C., et al. Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol 2007, 31:1050-1058.
33. Hoefnagel J.J., Vermeer M.H., Jansen P.M., et al. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: Further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol 2003, 149:1183-1191.
34. Oschlies I., Salaverria I., Mahn F., et al. Pediatric follicular lymphoma-A clinico-pathological study of a population-based series of patients treated within the NHL-BFM (Berlin-Frankfurt-Munster) multicenter trials. Haematologica 2009, 95:253-259.
35. Lorsbach R.B., Shay-Seymore D., Moore J., et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002, 99:1959-1964.
36. Swerdlow S.H. Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. Am J Clin Pathol 2004, 122(suppl):S98-S109.
37. Cong P., Raffeld M., Teruya-Feldstein J., et al. In situ localization of follicular lymphoma: Description and analysis by laser capture microdissection. Blood 2002, 99:3376-3382.
38. Adam P., Katzenberger T., Eifert M., et al. Presence of preserved reactive germinal centers in follicular lymphoma is a strong histopathologic indicator of limited disease stage. Am J Surg Pathol 2005, 29:1661-1664.
39. Campo E., Swerdlow S.H., Harris N., et al. The 2008 WHO Classification of Lymphoid Neoplasms and beyond-Evolving concepts and practical applications. Blood, epub before print 7 February 2011.
40. Buske C., Hoster E., Dreyling M., et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006, 108:1504-1508.
41. Solal-Celigny P., Roy P., Colombat P., et al. Follicular lymphoma international prognostic index. Blood 2004, 104:1258-1265.
42. Shustik J., Quinn M., Connors J.M., et al. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol, epub before print 9 November 2010.
43. Hsi E.D., Mirza I., Lozanski G., et al. A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. Arch Pathol Lab Med 2004, 128:863-868.
44. Koster A., Tromp H.A., Raemaekers J.M., et al. The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica 2007, 92:184-190.
45. Glas A.M., Kersten M.J., Delahaye L.J., et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005, 105:301-307.
46. de Jong D., Koster A., Hagenbeek A., et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009, 94:70-77.
47. Carreras J., Lopez-Guillermo A., Roncador G., et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009, 27:1470-1476.
48. Wahlin B.E., Aggarwal M., Montes-Moreno S., et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-Positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010, 16:637-650.
49. + T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007, 13:388-397.
50. Taskinen M., Karjalainen-Lindsberg M.L., Leppa S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood 2008, 111:4664-4667.
51. Farinha P., Masoudi H., Skinnider B.F., et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005, 106:2169-2174.
52. Farinha P., Kyle A.H., Minchinton A.I., et al. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 2010, 95:2157-2160.
53. Attygalle A., Al Jehani R., Diss T.C., et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 2002, 99:627-633.
54. van Dongen J.J., Langerak A.W., Bruggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003, 17:2257-2317.
55. Berget E., Helgeland L., Molven A., et al. Detection of clonality in follicular lymphoma using formalin-fixed, paraffin-embedded tissue samples and BIOMED-2 immunoglobulin primers. J Clin Pathol 2011, 64:37-41.
56. Schwaenen C., Viardot A., Berger H., et al. Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer 2009, 48:39-54.